Compare Rocket Lab USA Inc (RKLB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Zoetis Inc — how do they compare? Rocket Lab USA Inc trades at $69.5 (market cap $43.19B), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.81% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| RKLB | ZTS | |
|---|---|---|
Market Cap | $43.19B | $31.59B |
Sector | Technology | Health |
52-Week High | $150.23 | $156.76 |
52-Week Low | $39.48 | $71.91 |
Enterprise Value | $41.94B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, with a bearish technical signal despite oscillators suggesting oversold conditions. The company reported a net loss of $198.21 million in 2025, though revenue grew to $601.80 million. Recent positive news includes a $266 million defense contract awarded on July 21, 2026, per Benzinga, providing a near-term catalyst amid broader sector volatility.
The outlook remains high-risk with negative profitability but strong analyst support; 75% recommend Buy with a $116.90 consensus target. Key risks include execution delays on the Neutron rocket and intense competition. Upside depends on contract execution and path to profitability, while downside stems from cash burn and market sentiment shifts.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
